lutathera
advanced accelerator applications - luteţiu (177lu) oxodotreotide - tumori neuroendocrine - alte produse radiofarmaceutice terapeutice - lutathera este indicat pentru tratamentul unresectable sau metastatic, progresivă, bine diferentiat (g1 și g2), somatostatina receptorilor pozitiv gastroenteropancreatic neuroendocrine tumori (gep‑nets) la adulti.
sertospan 5 mg/2mg/ml suspensie injectabilă
world medicine ltd - betamethasonum - suspensie injectabilă - 5 mg/2mg/ml
octicide 1 mg/g+20 mg/g
profarma-produkt, s.r.o. - republica ceha - combinatii - spray cut., sol. - 1mg/g+20mg/g - antiseptice si dezinfectante compusi quaternari de amoniu
fludeoxiglucoză (18f) monrol 200-2200 mbq/ml soluţie injectabilă
monrol europe srl, s.c. - fludeoxyglucosum (18f) - soluţie injectabilă - 200-2200 mbq/ml
mon.fdg (18f) 250 mbq/ml soluţie injectabilă
eczacıbaşı monrol nükleer Ürünler sanayi ve ticaret a.Ş. - fludeoxyglucosum (18f) - soluţie injectabilă - 250 mbq/ml
diprophos
organon heist bv - belgia - betamethasonum - susp. inj. - 7mg/ml - corticosteroizi sistemici glucocorticoizi
dexametazonă 4 mg/ml soluţie injectabilă
uzina experimentală gnŢls srl - dexamethasonum - soluţie injectabilă - 4 mg/ml
fdg-rmc 185 mbq/ml
ruder medikol ciklotron d.o.o. - croatia - fludeoxiglucoza (18f) - sol. inj. - 185mbq/ml - preparate pentru detectarea tumorilor alte radiofarmaceutice pt. detectarea tumorilor
pluvicto
novartis europharm limited - lutetium (177lu) vipivotide tetraxetan - neoplasmele prostatice, rezistent la castrare - produse radiofarmaceutice terapeutice - pluvicto in combination with androgen deprivation therapy (adt) with or without androgen receptor (ar) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with ar pathway inhibition and taxane based chemotherapy.